Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06348134
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-04
First Post:
2024-03-29
Brief Title:
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2 Breast Cancer Before and After Surgery
Sponsor:
University of Chicago
Organization:
University of Chicago
Study Overview
Official Title:
Assessing the Efficacy and Safety of Optimal Neoadjuvant to Adjuvant Anti-HER2- Based Therapy in Nigerian Women With HER2 Breast Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Doctors leading this study would like to learn about providing cancer treatmenttherapies to Nigerian women with breast cancer based on their human epidermal growth factor receptor 2 HER2 status This study will focus on the efficacy and safety of anti-HER2 cancer treatment before and after surgery
Detailed Description:
Doctors leading this study would like to learn about providing cancer treatmenttherapies to Nigerian women with breast cancer based on their human epidermal growth factor receptor 2 HER2 status This study will focus on the efficacy and safety of anti-HER2 cancer treatment before and after surgery Participants with HER2-positive breast cancer will receive a combination of trastuzumab with pertuzumab PHESGO plus chemotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None